NYSE •
Healthcare •
Biotechnology •
Quote as of 06/09/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization3.26 mln
Float10.72 mln
Earnings Date08/07/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
46
/ 100
Slightly lagging
Debt / Equity
0.46
Low leverage
ROE
-391
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Founded in 2014 and based in San Diego, California, Calidi Biotherapeutics is a clinical-stage company focused on using stem cells to deliver cancer-fighting viruses directly to tumors. Its most advanced treatment, CLD-101, is currently being tested in clinical trials for patients with high-grade brain cancer, while several other therapies targeting solid tumors and lung cancer are in earlier stages of development. The company's approach is built around proprietary platforms designed to make these viral treatments more effective and better tolerated by patients.
